Abstract
The safety and toxicokinetics of SCH 721015, an adenovirus encoding the human interferon alpha-2b gene, and Syn3 (SCH 209702), a novel excipient, were assessed in cynomolgus monkeys administered intravesical doses of 2.5 × 10E11 or 1.25 × 10E13 particles SCH 721015 in 25 mg Syn3 or 25 mg Syn3 alone on study days 1 and 91. There was no systemic toxicity. Monkeys dosed with SCH 721015 in Syn3 were positive for SCH 721015-specific DNA in the urine for 2 to 3 days following each dose and had interferon alpha-2b protein in the urine for 1–3 days after a single dose and in fewer animals after a second dose. Intracystic administration was associated with inflammation and focal/multifocal ulceration in the urinary bladder and irritation in the ureters and urethra at necropsy. The physical trauma from catheterization and filling/emptying of the bladder was likely a contributing factor and Syn3 exacerbated the trauma. There was nearly complete resolution of these findings 2 months after the last dose. The trauma to the bladder likely contributed to low, transient systemic exposure to Syn3, SCH 721015 and human interferon protein. The results of this study support the clinical investigation of SCH 721015 in Syn3.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
American Cancer Society. Cancer Facts and Figures 2010. American Cancer Society: Atlanta, GA, 2010.
Gontero P, Bohle A, Malmstrom PU, O’Donnell MA, Oderda M, Sylvester R et al. The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer. Eur Urol 2010; 57: 410–429.
Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992; 147: 596–600.
Dovedi SJ, Davies BR . Emerging targeted therapies for bladder cancer: a disease waiting for a drug. Cancer Metastasis Rev 2009; 28: 355–367.
Tao Z, Connor RJ, Ashoori F, Dinney CP, Munsell M, Philopena JA et al. Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation. Cancer Gene Ther 2006; 13: 125–130.
Benedict WF, Tao Z, Kim CS, Zhang X, Zhou JH, Adam L et al. Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther 2004; 10: 525–532.
Nagabhushan TL, Maneval DC, Benedict WF, Wen SF, Ihnat PM, Engler H et al. Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer. Cytokine Growth Factor Rev 2007; 18: 389–394.
Connor RJ, Engler H, Machemer T, Philopena JM, Horn MT, Sutjipto S et al. Identification of polyamides that enhance adenovirus-mediated gene expression in the urothelium. Gene Therapy 2001; 8: 41–48.
Yamashita M, Rosser CJ, Zhou J, Zhang X, Connor RJ, Engler H et al. Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. Cancer Gene Ther 2002; 9: 687–68; 691.
Morrissey RE, Horvath C, Snyder EA, Patrick J, MacDonald JS . Rodent nonclinical safety evaluation studies of SCH 58500, an adenoviral vector for the p53 gene. Toxicol Sci 2002; 65: 266–275.
Morrissey RE, Horvath C, Snyder EA, Patrick J, Collins N, Evans E et al. Porcine toxicology studies of SCH 58500, an adenoviral vector for the p53 gene. Toxicol Sci 2002; 65: 256–265.
Barnard DL . Technology evaluation: SCH-58500, Canji. Curr Opin Mol Ther 2000; 2: 586–592.
Kuball J, Wen FS, Leissner J, Atkins D, Meinhardt P, Quijano E et al. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol 2002; 20: 957–965.
Connor RJ, Anderson JM, Machemer T, Maneval DC, Engler H . Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens. Urology 2005; 66: 224–229.
U.S. Food and Drug Administration. The Nonclinical Laboratory Studies Good Laboratory Practice Regulations issued by the U.S. Food and Drug Administration (Title 21 of the Code of Federal Regulations, Part 58), effective 20 June 1979.
National Research Council of the National Academies, Institute for Laboratory Animal Research. Guide for the Care and Use of Laboratory Animals. National Academy Press: Washington, DC, 1996.
Ahmed CMI, Sugarman BJ, Duane E, Johnson R, Bookstein E, Saha DP et al. In vivo tumor suppression by adenovirus-mediated interferon a 2b gene delivery. Human Gene Ther 1999; 10: 77–84.
Acknowledgements
We thank the following for their assistance during the conduct of the study: Erika Frank, Diane McAllister, Erlinda Quijano, Mei Vaillencourt and Shu Fen Wen. We also thank Dr Dinesh Sinha and Brian Lee for their assistance with the photomicrographs.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Veneziale, R., Kishnani, N., Nelson, J. et al. Toxicity and exposure of an adenovirus containing human interferon alpha-2b following intracystic administration in cynomolgus monkeys. Gene Ther 19, 742–751 (2012). https://doi.org/10.1038/gt.2011.116
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/gt.2011.116
